자궁선근증에서 혈청 CA-125치와 월경곤란증 정도의 병변 깊이와의 관계
The association of serum CA-125 level and severity of dysmenorrhea with lesion depth in adenomyosis
1
조회
0
다운로드
4
인용
0
참고문헌
키워드
초록
목적 : 본 연구는 자궁선근증에서 월경곤란증 정도와 수술 전 혈청 CA-125 수치의 침윤 깊이와의 관계를 알아보고자 한다. 연구 방법 : 전자궁절제술을 시행하고 조직병리학적으로 다른 병변이 포함되지 않고 자궁선근증만을 진단 받은 68명의 여성을 대상으로 후향적 조사를 하였다. 자궁 조직을 자궁선근증의 침윤 깊이에 따라 4군, A군은 자궁선근증이 자궁 근층의 25%까지 침범한 조직들로 구성하고, B군은 26-50%, C군 51-75%, D군>75%으로 구분하여 수술 전 검사한 혈청 CA-125 수치와 월경곤란증 정도를 구두 평가치를 사용, 그 상관관계를 ANOVA test, Fisher's Exact test를 이용해 분석하였다. 결과 : A-D군의 월경곤란증 정도의 상관관계는 각 군간에 연관성을 찾을 수 없었으며 (Fisher's Exact test p=0.7394), 혈청 CA-125 수치와는 자궁선근증의 침윤 깊이가 클수록 평균치가 증가하였다 (ANOVA test p=0.0441). 결론 : 이 연구에서 자궁선근증의 침윤 깊이는 혈청 CA-125 수치와 유의한 연관성이 있었고, 월경곤란증 정도와는 그렇지 못한 것으로 나타났다. 그러므로, 혈청 CA-125는 수술 전에 자궁선근증을 다루는데 유용한 척도가 될 수 있을 것으로 생각된다.
Abstract
Objective : To evaluate the association of level of CA-125 and severity of dysmenorrhea with lesion depth in adenomyosis. Methods : Sixty-eight women who had undergone hysterectomy and were found to have pure adenomyosis on histopathologic examination were reviewed retrospectively. Specimens were stratified according to the degree of adenomyosis penetration into 4 groups: group A consisted of specimens with adenomyosis penetration into myometrium of up to 25%; group B, 26-50%; group C, 51-75%, and group D, >75%. All women were submitted to serum determination of CA-125. Severity of dysmenorrhea was assessed by means of a modification of 10-point verbal rating scale. Results : Each group was not correlated with severity of dysmenorrhea (p=0.7394 Fisher's exact test). The means of serum CA-125 levels was increased corresponding to depth of adenomyosis (p=0.0441 ANOVA test). Conclusion : In this study, serum CA-125 level is associated with the depth lesion and severity of dysmenorrhea is not. Therefore, the level of serum CA-125 might be useful indicator in management of adenomyosis before surgery.
참고문헌 (14)
- Molitor JJ, "Adenomyosis: A clinical and pathologic appraisal", 110, pp.275~ (1971)
- Azziz R, "Adenomyosis:Current perspectives", 16, pp.221~235 (1989)
- The American Fertility Society, "Revised American Fertility Society Classification of Endometriosis: 1985", 43, pp.351~352 (1985), The American Fertility Society
- Trespidi L, "Eendo-metriosis and pelvic pain:relation to disease stage and localization", 65, pp.299~304 (1996)
- Usubutun A, "Correlations between Extent and Spread of Adenomyosis and Clinical Symptoms", 54, pp.213~216 (2002)
- Pittaway DE, "Serum CA-125 in women with endometriosis and chronic pelvic pain", 51, pp.68~70 (1989)
- Chen FP, "The use of serum CA-125 as a marker for endome-triosis in patients with dysmenorrhea for monitoring therapy and for recurrence of endometrios", 11, pp.665~670 (1998)
- Biberoglu KO, "Dosage aspects of danazol therapy in endometriosis:short-term effectiveness", 139, pp.645~650 (1981)
- Kilkku P, "Non-specificity of symptoms related to adenomyosis. A prospective comparative survey", 63, pp.229~231 (1984)
- Manalo-Estrella P, "The elusive adenomyosis of the uterus", 112, pp.583~ (1972)
- Pittaway DE, "Serum CA-125 antigen levels increase during menses", 156, pp.75~ (1987)
- Nishida M, "Relationship between the onset of dysmenorrhea and histologic findings in adenomyosis", 165, pp.229~231 (1991)
- Harada T, "Usefulness of CA19-9 versus CA125 for the diagnosis of endometriosis", 78, pp.733~739 (2002)
- Ravel R, "Manual of Clinical Laboratory medicine. 6th ed", pp.580~ (1995), Mosby